Loading...
Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update
Intravenous vernakalant has recently been approved in Europe as an atrial-selective antiarrhythmic drug for the conversion of recent-onset atrial fibrillation (AF). It inhibits atrial-selective K(+) currents (I(K,ACh) and I(Kur)) and causes rate-dependent atrial-predominant Na(+) channel block, with...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove Medical Press
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3639220/ https://ncbi.nlm.nih.gov/pubmed/23637539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S43720 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|